Skip to content

26 Weeks' Dietary Supplementation With DHA- and EPA-enriched Oils on Memory Consolidation in Healthy Adults

Efficacy Evaluation of 26 Weeks' Dietary Supplementation With DHA- and EPA-enriched Oils on Memory Consolidation in Healthy Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03592251
Enrollment
168
Registered
2018-07-19
Start date
2017-08-01
Completion date
2018-11-30
Last updated
2019-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Memory Consolidation

Brief summary

The purpose of this study is to investigate the effects of EPA- and DHA-enriched omega-3 polyunsaturated fatty acid dietary supplements on overnight verbal and visual memory consolidation as well as morning alertness before and after 26 weeks of supplementation

Interventions

DIETARY_SUPPLEMENTOlive Oil Placebo

6 months placebo supplementation

DIETARY_SUPPLEMENTEPA-rich

6 months placebo supplementation

DIETARY_SUPPLEMENTDHA-rich

6 months placebo supplementation

Sponsors

BASF
CollaboratorINDUSTRY
Northumbria University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
25 Years to 49 Years
Healthy volunteers
Yes

Inclusion criteria

* Aged 25 to 49 years inclusive * Males and females * Self-report of good health

Exclusion criteria

* English is not first language (some of the cognitive tasks have only been validated in native English speakers) * Habitual consumption of oily fish exceeds one fish meal per week * Habitual consumption of n-3 dietary supplements in the previous 6 months * Habitual use of dietary supplements within the last month (defined as more than 3 consecutive days or 4 days in total; some supplements that do not impact upon cognitive function e.g. garlic, protein, calcium are allowed. Please check with the research team if you are unsure) * Are a smoker or consume any nicotine replacement products (e.g. chewing gum, e-cigarettes)? * Food allergies or sensitivities to any of the ingredients contained in the investigational product or any other foodstuff * Pregnant, trying to get pregnant or breast feeding * Body Mass Index outside of the range 18-35 kg/m2 * High blood pressure (systolic over 159 mm Hg or diastolic over 99 mm Hg) * Currently taking blood pressure medication * Currently taking blood thinning medication (e.g. aspirin, warfarin, heparin) * Have a respiratory disorder that requires regular medication (Note: participants with asthma who only take their medication occasionally/as required are eligible for this study) * Have frequent migraines that require medication (more than or equal to 1 per month) * History or current diagnosis of drug/alcohol abuse * History of kidney or liver disease, or other severe diseases of the gastrointestinal tract (e.g. iron accumulation, iron utilization disorders, hypercalcaemia, hypercalcaemia), that are likely to interfere with metabolism/absorption/secretion of the product under investigation * History of neurological or psychiatric illness (excluding depressive illness and anxiety) * History of head trauma * Sleep disturbances and/or are taking sleep aid medication * Blood disorders (e.g. anaemia, haemophilia, thrombocytosis) * Diagnosis of type I or type II diabetes * Heart disorder, or vascular illness * Current diagnosis of depression and/or anxiety * Over- or under-active thyroid * Chronic gastrointestinal problems (e.g. Inflammatory Bowel Disease, Irritable Bowel Syndrome, celiac disease) * Any known active infections * Diagnosed with or may be at risk of having syphilis, hepatitis, the Human T - lymphotropic virus or the Human Immunodeficiency Virus * Current or past breast cancer diagnosis and/or a mastectomy * Health condition that would prevent fulfilment of the study requirements * Currently participating in or in the past 4 weeks participated in other clinical or nutrition intervention studies

Design outcomes

Primary

MeasureTime frameDescription
Computerised Location Learning task26 monthsDelayed recall accuracy
Verbal Learning task26 monthsDelayed recall accuracy

Secondary

MeasureTime frameDescription
Peg and Ball/Tower of London taskpre, Mid and post dose measuresPlanning time (ms)
Simple reaction time task26 monthsreaction time speed from a simple reaction task
Computerised Location Learning task26 monthsLearning index
Subjective Alertness26 monthsSubjective ratings of alertness upon waking on a visual analogue scale (0-100 with 100 denoting the most alert the participant has ever felt in their life)
Digit vigilance task26 monthsaccuracy (%)
Verbal Learning task26 monthsLearning index

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026